I thank colleagues from across the chamber who signed the motion allowing today’s debate, and I commend a number of fellow elected representatives who have campaigned on the issue for a number of years—longer than I have—including Kenneth Gibson MSP and Patricia Gibson MP. I also pay tribute to and welcome the continuing good work of Action on Pre-eclampsia.
Pre-eclampsia, which most often demonstrates itself through high blood pressure, is the most common of the serious complications of pregnancy. Mild pre-eclampsia affects up to 10 per cent of first-time pregnancies and severe cases affect one to two in 100 pregnancies. It is caused by a poorly functioning placenta—an organ that joins the mother and baby and supplies the baby with nutrients and oxygen from the mother’s blood.
Although we do not know exactly the root cause of pre-eclampsia, medical science is expanding our knowledge every day. By definition, pre-eclampsia occurs after 20 weeks—earlier in very rare cases—and the majority of cases occur in the third trimester. This multisystem disorder can affect different parts of the body including the liver, kidneys and the cardiovascular and clotting systems.
I therefore decided to bring this debate to Parliament to discuss the pathways currently available for expectant mothers and the available opportunities to improve the diagnosis of the condition and the care of Scottish mothers who have it. The current clinical pathway in Scotland for pre-eclampsia includes taking blood pressure and urine measurements, but both blood pressure and proteinuria are relatively poor at predicting its clinical onset and progression. Indeed, it is estimated that 70 per cent of women admitted to hospital with suspected pre-eclampsia do not have the condition. Understandably, that has cost implications for our NHS and puts those women and their families under significant and unnecessary stress in many cases, as well as the inconvenience of their being hospitalised.
There is a solution, though, which is the use of placental growth factor testing, which I will discuss. It has been part of the National Institute for Health and Care Excellence guidelines since 2016. In 2019, NHS England announced the roll-out of PIGF testing through the rapid uptake programme in order to help rule out pre-eclampsia, which was a welcome step forward in England. The use of PIGF has been shown to reduce demand on maternity services, improve patient safety and patient experience, reduce admissions and reduce unnecessary in-patient monitoring services.
A previous trial called the PARROT trial—“Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial”—demonstrated that, compared to traditional methods, the PIGF test, alongside blood pressure and urine checks, reduced the average time to diagnosis from 4.1 days to 1.9 days. It also significantly cut the rate of serious maternal complications and maternal death, with no increased risk to babies and no increase in premature deliveries or neonatal unit admissions.
As things stand, that test is not routinely available in Scotland and many mothers-to-be and families here think that that disparity in care between women in England and women in Scotland is unfair, and I share their concerns. The Scottish Government’s position to date—I hope that the minister will clarify this during the debate—is that ministers need to wait until the results of a second trial—PARROT-2—are known, before adopting routine PIGF tests. However, that trial might take up to five years to report and there is already strong clinical evidence to recommend using the PIGF test. In addition, it is supported in national clinical guidelines, including NICE diagnostic evidence 23—DG23—which states that the test,
“used with standard clinical assessment”
is
“recommended to help rule-out pre-eclampsia in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation.”
Furthermore, the PARROT-2 trial, the results of which ministers have said they want to wait for, will look only at the effectiveness of repeat PIGF testing. However, given that no PIGF testing is taking place in Scotland, I do not think that the trial will add the value that ministers have suggested that they are waiting to see.
What campaigners and I want to emphasise is that, although the PIGF test is a powerful tool in ruling out pre-eclampsia, it is not a certain diagnosis of the condition. However, the tests are highly accurate in ruling out the chances of a woman developing pre-eclampsia requiring delivery in the next 14 days. Care can therefore be targeted and unnecessary admissions reduced, while women who are at greater risk can receive the appropriate surveillance to reduce possible complications. NICE’s economic evaluation of the test suggests a potential cost reduction of between £2,488 and £2,896 per patient, compared to standard clinical assessment, depending on the test used. The potential saving and investment for the NHS is therefore significant.
I believe strongly that mums-to-be in Scotland who might be at risk of pre-eclampsia need as much support as possible and should be able to access the best possible ways of ruling out the condition. PIGF testing is working highly successfully in England and is helping many pregnant women and reducing pressure and costs on the English NHS. It is unacceptable that pregnant women in Scotland cannot access those tests routinely and that there appears to be no clear path identifying their adoption here.
I hope that the debate presents an opportunity for ministers to consider the success of the testing elsewhere and the clear NICE guidelines, to review their current position and to introduce the tests so that women in Scotland can have the same level of treatment as those in England—anything else will not be acceptable.
17:09